How Sanofi wants to become the leader in immunology

Frankfurt The pharmaceutical group Sanofi sees itself on a sustainable growth course and is setting new goals. “We will be the leading company in immunology,” says company boss Paul Hudson. The Briton, who took over the management of Europe’s third-largest drugmaker in autumn 2019, now expects Sanofi to generate sales of more than 22 billion euros in the field by the end of the decade. The main product Dupixent, a drug against atopic dermatitis (neurodermatitis), alone is said to contribute more than 13 billion euros.

Immunology deals with diseases that are triggered by excessive activity of the immune system. Healthy tissue is attacked by the body’s own defense cells. We are therefore also talking about “autoimmune diseases”. These include rheumatism, multiple sclerosis (MS), psoriasis or chronic intestinal inflammation.